Literature DB >> 18586446

Factors associated with stroke or death after carotid endarterectomy in Northern New England.

Philip P Goodney1, Donald S Likosky, Jack L Cronenwett.   

Abstract

OBJECTIVE: This study investigated risk factors for stroke or death after carotid endarterectomy (CEA) among hospitals of varying type and size participating in a regional quality improvement effort.
METHODS: We reviewed 2714 patients undergoing 3092 primary CEAs (excluding combined procedures or redo CEA) at 11 hospitals in Northern New England from January 2003 through December 2007. Hospitals varied in size (25 to 615 beds) and comprised community and teaching hospitals. Fifty surgeons reported results to the database. Trained research personnel prospectively collected >70 demographic and clinical variables for each patient. Multivariate logistic regression models were used to generate odds ratios (ORs) and prediction models for the 30-day postoperative stroke or death rate.
RESULTS: Across 3092 CEAs, there were 38 minor strokes, 14 major strokes, and eight deaths (5 stroke-related) < or =30 days of the index procedure (30-day stroke or death rate, 1.8%). In multivariate analyses, emergency CEA (OR, 7.0; 95% confidence interval [CI], 1.8-26.9; P = .004), contralateral internal carotid artery occlusion (OR, 2.8; 95% CI, 1.3-6.2; P = .009), preoperative ipsilateral cortical stroke (OR, 2.4; 95% CI, 1.1-5.1; P = .02), congestive heart failure (OR, 1.6; 95% CI, 1.1-2.4, P = .03), and age >70 (OR, 1.3; 95% CI, 0.8-2.3; P = .315) were associated with postoperative stroke or death. Preoperative antiplatelet therapy was protective (OR, 0.4; 95% CI, 0.2-0.9; P = .02). Risk of stroke or death varied from <1% in patients with no risk factors to nearly 5% with patients with > or =3 risk factors. Our risk prediction model had excellent correlation with observed results (r = 0.96) and reasonable discriminative ability (area under receiver operating characteristic curve, 0.71). Risks varied from <1% in asymptomatic patients with no risk factors to nearly 4% in patients with contralateral internal carotid artery occlusion (OR, 3.2; 95% CI, 1.3-8.1; P = .01) and age >70 (OR, 2.9; 95% CI, 1.0-4.9, P = .05). Two hospitals performed significantly better than expected. These differences were not attributable to surgeon or hospital volume.
CONCLUSION: Surgeons can "risk-stratify" preoperative patients by considering the variables (emergency procedure, contralateral internal carotid artery occlusion, preoperative ipsilateral cortical stroke, congestive heart failure, and age), reducing risk with antiplatelet agents, and informing patients more precisely about their risk of stroke or death after CEA. Risk prediction models can also be used to compare risk-adjusted outcomes between centers, identify best practices, and hopefully, improve overall results.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18586446     DOI: 10.1016/j.jvs.2008.05.013

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  35 in total

1.  Variation in the use of lower extremity vascular procedures for critical limb ischemia.

Authors:  Philip P Goodney; Lori L Travis; Brahmajee K Nallamothu; Kerianne Holman; Bjoern Suckow; Peter K Henke; F Lee Lucas; David C Goodman; John D Birkmeyer; Elliott S Fisher
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2011-12-06

2.  The need for treatment of hemodynamic instability following carotid endarterectomy is associated with increased perioperative and 1-year morbidity and mortality.

Authors:  Tze-Woei Tan; Mohammad H Eslami; Jeffrey A Kalish; Robert T Eberhardt; Gheorghe Doros; Philip P Goodney; Jack L Cronenwett; Alik Farber
Journal:  J Vasc Surg       Date:  2013-08-30       Impact factor: 4.268

3.  Carotid endarterectomy should not be based on consensus statement duplex velocity criteria.

Authors:  Jesse A Columbo; Bjoern D Suckow; Claire L Griffin; Jack L Cronenwett; Philip P Goodney; Timothy G Lukovits; Robert M Zwolak; Mark F Fillinger
Journal:  J Vasc Surg       Date:  2017-02-09       Impact factor: 4.268

Review 4.  Roles for specialty societies and vascular surgeons in accountable care organizations.

Authors:  Philip P Goodney; Elliott S Fisher; Richard P Cambria
Journal:  J Vasc Surg       Date:  2012-03       Impact factor: 4.268

5.  Impact of practice patterns in shunt use during carotid endarterectomy with contralateral carotid occlusion.

Authors:  Philip P Goodney; Jessica B Wallaert; Salvatore T Scali; David H Stone; Virendra Patel; Palma Shaw; Brian W Nolan; Jack L Cronenwett
Journal:  J Vasc Surg       Date:  2011-11-03       Impact factor: 4.268

Review 6.  Perioperative stroke.

Authors:  Phillip Vlisides; George A Mashour
Journal:  Can J Anaesth       Date:  2015-09-21       Impact factor: 5.063

7.  In-hospital versus postdischarge adverse events following carotid endarterectomy.

Authors:  Margriet Fokkema; Rodney P Bensley; Ruby C Lo; Allan D Hamden; Mark C Wyers; Frans L Moll; Gert Jan de Borst; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2013-02-04       Impact factor: 4.268

8.  Accuracy of administrative data versus clinical data to evaluate carotid endarterectomy and carotid stenting.

Authors:  Rodney P Bensley; Shunsuke Yoshida; Ruby C Lo; Margriet Fokkema; Allen D Hamdan; Mark C Wyers; Elliot L Chaikof; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2013-03-13       Impact factor: 4.268

9.  Optimal selection of asymptomatic patients for carotid endarterectomy based on predicted 5-year survival.

Authors:  Jessica B Wallaert; Jack L Cronenwett; Daniel J Bertges; Andres Schanzer; Brian W Nolan; Randall De Martino; Jens Eldrup-Jorgensen; Philip P Goodney
Journal:  J Vasc Surg       Date:  2013-03-07       Impact factor: 4.268

10.  Intraoperative use of dextran is associated with cardiac complications after carotid endarterectomy.

Authors:  Alik Farber; Tze-Woei Tan; Denis Rybin; Jeffrey A Kalish; Naomi M Hamburg; Gheorghe Doros; Philip P Goodney; Jack L Cronenwett
Journal:  J Vasc Surg       Date:  2013-01-18       Impact factor: 4.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.